ProEn Therapeutics, which develops antibody-drug conjugates (ADCs), said Monday that it has completed attracting a strategic investment from Kolmar Korea Holdings.The investment amount was not disclosed per the agreement between the two companies.The investment is part of an open innovation program
GSK Korea's inhalation-type triple combination asthma medicines Trelegy 100 Ellipta (fluticasone furoate/umeclidinium/vilanterol) and Trelegy200 Ellipta will get health insurance benefits starting this month.According to a notice by the Ministry of Health and Welfare and the Health Insurance Review
Samjin Pharmaceutical announced a strategic investment of 1 billion won ($751,371) in Neurophet, a company specializing in AI solutions for brain disorder imaging, to fight dementia and stroke.Under the accord, the two companies seek to leverage Samjin’s extensive research resources, infrastructure,
The Korea Drug Research Association held the 25th Korea New Drug Development Award Ceremony in Seoul last Thursday.At the ceremony, Yuhan Corp., which developed the non-small cell lung cancer (NSCLC) treatment Leclaza, and GC Biopharma’s immune disease treatment Alyglo co-won the grand prize in the
Hugel said it received approval from the U.S. FDA for its botulinum toxin product, Letybo, in 50-unit and 100-unit dosages.This FDA approval marks a significant development for Hugel, following its third attempt to gain approval for Letybo.The company's journey to this point involved addressing feed
Pharmbio Korea will exclusively sell Clipper (beclomethasone dipropionate), an original ulcerative colitis treatment from Italian pharmaceutical company Chiesi, in Korea.Clipper is a steroidal ulcerative colitis treatment, a long-acting extended-release tablet that provides the anti-inflammatory ben
Biologic agent Dupixent (dupilumab) has emerged as a new treatment option for moderate-to-severe nodular pruritic rash (prurigo nodularis), for which existing treatments, such as topical steroids and systemic immunosuppressants, have shown little treatment effects.On Wednesday, Sanofi Korea held a n
Kolon Life Science said it has decided to appeal to the Supreme Court against the revocation of the manufacturing and sales license for its knee osteoarthritis cell and gene therapy, Invossa-K Inj.This move comes after the company faced defeats in both the district and appellate courts.Most recently
Celltrion said Thursday that it has completed submitting a marketing authorization application for CT-P47, a biosimilar to Actemra (tocilizumab) for treating autoimmune diseases, to the Ministry of Food and Drug Safety (MFDS).Celltrion has applied for the marketing authorization of CT-P47 for the fu
PARP (poly ADP-ribose polymerase) inhibitors have recently emerged as a new treatment option for metastatic castration-resistant prostate cancer (mCRPC) with a poor prognosis and are expected to contribute significantly to improving survival rates.However, they remain far beyond the reach of most Ko
BeiGene, a global biotech firm founded in 2010 in Beijing, is strengthening its global presence by expanding its workforce and boosting sales.The company is waiting for the U.S. Food and Drug Administration (FDA) to approve its anti-PD-1 immuno-oncology drug Tevimbra (tislelizumab) this year, drawin
Starting next month, biliary tract cancer patients can add the anti-PD-L1 immunotherapy Imfinzi (durvalumab) at their own expense to the existing gemcitabine/cisplatin (GemCis) chemotherapy regimen for the first-line treatment of locally progressive or metastatic biliary tract cancer.It was part of
Roche Korea hosted a two-day RISE (Roche Initiated Scientific Exchange) symposium on Thursday and Friday last week, shedding light on the clinical significance of the pioneering bispecific antibodies for blood cancer, Columvi (ingredient: glofitamap) and Lunsumio (mosunetuzumab).Comprising five sess
Medytox has encountered a significant setback as the U.S. FDA has declined the biologics license application (BLA) for its innovative non-animal liquid botulinum toxin product, MT10109L, aimed at reducing moderate to severe glabellar (forehead) and lateral canthal (crow's feet) lines.The refusal, da
The first FGFR inhibitor for bladder cancer, Balversa (erdafitinib), will soon be launched in Korea.According to industry sources on Monday, Janssen Korea is gearing up to release Balversa without reimbursement in late March.Balversa is an FGFR (fibroblast growth factor receptor) inhibitor approved
Celltrion once again demonstrated the competitiveness of its Remsima SC at the 2024 European Crohn's and Colitis Organization (ECCO) congress in Stockholm, Sweden, from last Wednesday to Saturday by receiving favorable reviews from overseas medical professionals.At the ECCO, attended by more than 8,
GC Cell has signed an agreement to transfer the processing technology of its flagship anticancer immune cell therapy, Immuncell-LC Injection, to BioCentriq, its U.S. affiliate, and a cell therapy CDMO company.Through this process technology transfer cooperation, GC Cell and Biocentriq expect to prov
JW Shinyak said Monday it has signed a collaborative research agreement with C&C Research Laboratories, a subsidiary of JW Pharmaceutical, to develop innovative anticancer cell therapies.Under the agreement, JW Shinyak will develop a new CAR-NK cell therapy targeting solid tumors with C&C Research L
CKD Bio said it has confirmed the non-inferiority of CKDB-501A, aimed at improving moderate to severe frown lines, compared to Botox through a phase 3 clinical trial's topline results.The analysis of the data revealed that the improvement rate for frown lines when frowning was 80.69 percent (117 out
LG Chem said Friday that the company opened an aesthetic “Solution Lab Center" in Caiting Hospital, which specializes in cosmetic surgery in Shanghai, to expand expand its educational support for YVOIRE (LG Chem's hyaluronic acid filler’s brand name) customers in China.LG Chem’s Executive Vice Presi